Investigating the link between psoriasis and cardiovascular disease: current evidence, therapeutic implications and perspectives.
Abstract Psoriasis; a chronic inflammatory disease is characterized by symmetric hyperkeratotic plaques affecting any part of the body. Psoriasis is nowadays considered as a systemic inflammation linked with several comorbidities as metabolic syndrome, depression, anxiety and increased prevalence of cardiovascular (CV) disease. The hypothesis that psoriasis is an independent CV risk factor leading to atherosclerosis via inflammation. is now widely accepted. Deciphering the underlying mechanisms interconnecting psoriasis and CV disease may have significant implications on treatment decisions. Accumulating evidence ...
Source: Current Vascular Pharmacology - May 23, 2020 Category: Drugs & Pharmacology Authors: Kapniari E, Papadimitriou P, Dalamaga M, Makavos G, Piaserico S, Egeberg A, Ikonomidis I, Papadavid E Tags: Curr Vasc Pharmacol Source Type: research

Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class.
Conclusions BBs differ within the class in so many ways that it is not only logical but also practical for real-life clinical practice that experts in the field make a list of the compelling indications for individual BBs. Time has come to incorporate our knowledge about BBs into a new approach of presenting these useful and very individual drugs. PMID: 32418526 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - May 18, 2020 Category: Drugs & Pharmacology Authors: Koracevic G, Micic S, Stojanovic M, Lovic D, Simic D, Colic M, Koracevic M, Stojkovic A, Paunovic M Tags: Curr Vasc Pharmacol Source Type: research

Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?
Abstract In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, immunology and related fields. These reviews discuss the cardiovascular complications of the main systemic autoimmune rheumatic diseases (ARDs). For example, the underlying pathogenetic mechanisms, the role of cardiovascular imaging and recommendations for prevention and management. These articles place inflammation as the key process, linking ca...
Source: Current Vascular Pharmacology - May 14, 2020 Category: Drugs & Pharmacology Authors: Manolis AS, Tzioufas AG Tags: Curr Vasc Pharmacol Source Type: research

Effects of Maternal Obesity On Placental Phenotype.
Abstract The incidence of obesity is rising rapidly worldwide with the consequence that more women are entering pregnancy overweight or obese. This leads to an increased incidence of clinical complications during pregnancy and of poor obstetric outcomes. The offspring of obese pregnancies are often macrosomic at birth although there is also a subset of the progeny that are growth restricted at term. Maternal obesity during pregnancy is also associated with cardiovascular, metabolic and endocrine dysfunction in the offspring later in life. As the interface between the mother and fetus, the placenta has a central ro...
Source: Current Vascular Pharmacology - May 13, 2020 Category: Drugs & Pharmacology Authors: Fowden A, Camm E, Sferruzzi-Perri A Tags: Curr Vasc Pharmacol Source Type: research

Prime Time for Lower Extremity Artery Disease.
PMID: 32340598 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 30, 2020 Category: Drugs & Pharmacology Authors: De Carlo M Tags: Curr Vasc Pharmacol Source Type: research

Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?
PMID: 32340599 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 30, 2020 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Mantzoros C Tags: Curr Vasc Pharmacol Source Type: research

Endothelial dysfunction and inflammatory markers of vascular disease.
Abstract Vascular diseases are the main reason for morbidity and mortality worldwide. As we known, the earlier phase of vascular diseases is endothelial dysfunction in humans. The endothelial tissues play an important role in inflammation, coagulation, and angiogenesis, via the organizing of ligand-receptor associations and the various mediators' secretion. We can use many inflammatory non-invasive tests (flow-mediated dilatation, epicedial fat thickness, carotid-intima media thickness, arterial stiffness and ankle-brachial index) for assessing the endothelial function. In addition, many biomarkers (ischemia modif...
Source: Current Vascular Pharmacology - April 21, 2020 Category: Drugs & Pharmacology Authors: Balta S Tags: Curr Vasc Pharmacol Source Type: research

New insights into the role of FGF-23 and Klotho in cardiovascular disease in chronic kidney disease patients.
Abstract Alterations of fibroblast growth factor 23 (FGF-23) and Klotho levels are considered to be the earliest biochemical abnormality of chronic kidney disease - mineral and bone disease (CKD-MBD) syndrome. Moreover, emerging data suggests that the dysregulated FGF-23 and Klotho axis has many effects on the cardiovascular (CV) system and contributes significantly to the increased CV morbidity and mortality rates of CKD patients. This review examines recent evidence on the role of FGF-23 and Klotho in the development and progression of CV complications of uremia namely cardiac hypertrophy, uremic cardiomyopathy ...
Source: Current Vascular Pharmacology - April 19, 2020 Category: Drugs & Pharmacology Authors: Memmos E, Papagianni A Tags: Curr Vasc Pharmacol Source Type: research

The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy - The Piece of a Much Larger Puzzle.
CONCLUSIONS: Predictive value of GFR CKD-EPI and creatinine concentration for a positive response to CRT were found relevant. PMID: 32286948 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 13, 2020 Category: Drugs & Pharmacology Authors: Dębska-Kozłowska A, Warchoł I, Książczyk M, Lubiński A Tags: Curr Vasc Pharmacol Source Type: research

Erectile dysfunction as a cardiovascular risk factor: time to step up?.
CONCLUSION: Accumulating evidence supports a strong predictive role of ED for CV events. Early identification of ED could allow for the optimal management of these patients to reduce the risk for a CV event to occur. PMID: 32286949 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 13, 2020 Category: Drugs & Pharmacology Authors: Imprialos K, Koutsampasopoulos K, Manolis A, Doumas M Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in Juvenile Idiopathic Arthritis.
Abstract Juvenile idiopathic arthritis (JIA), is a term used to describe a group of inflammatory disorders beginning before the age of 16 years. Although for the majority of children remission is achieved early, those with systemic or polyarticular form of the disease may present persistent symptoms in adulthood. Considering that there is overlap in the pathogenesis of JIA with adult rheumatic diseases, concerns have been raised as to whether JIA patients could be at increased cardiovascular (CV) risk in the long-term. In this review, we summarize evidence for CV involvement in JIA and present data on CV risk fact...
Source: Current Vascular Pharmacology - April 8, 2020 Category: Drugs & Pharmacology Authors: Arsenaki E, Georgakopoulos P, Mitropoulou P, Koutli E, Thomas K, Charakida M, Georgiopoulos G Tags: Curr Vasc Pharmacol Source Type: research

Pulse wave velocity assessment for cardiovascular risk prognostication in ESKD: weighing recent evidence.
CONCLUSION: Despite the strong pathophysiological relevance of arterial stiffness as a mediator of CV disease in ESKD, the assessment of aortic PWV for CV risk stratification in this population appears to be of limited value. Whether aortic PWV assessment is valuable in guiding CV risk factor management and whether such a therapeutic approach is translated into improvement in clinical outcomes is an issue of clinical relevance that warrants investigation in properly-designed randomized trials. PMID: 32242783 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - April 3, 2020 Category: Drugs & Pharmacology Authors: Georgianos PI, Vaios V, Eleftheriadis T, Zebekakis PE, Liakopoulos V Tags: Curr Vasc Pharmacol Source Type: research

Coronary Calcium Risk Score and Cardiovascular Risk.
Abstract The association between presence of coronary artery calcium (CAC) and risk of coronary artery disease (CAD) has been appreciated for decades. In this review, we critically appraise the role of CAC based on computerized tomography in contemporary risk stratification. Available evidence suggests that measurement of CAC is a useful modality in many patients for more precise risk stratification and prognostic determination. Whether newer CAC score incorporating extra coronary calcification, will add incremental value, especially for stroke and other non-coronary vascular outcomes needs prospective study. ...
Source: Current Vascular Pharmacology - April 3, 2020 Category: Drugs & Pharmacology Authors: Lehker A, Mukherjee D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis.
Abstract Hemodialysis (HD) remains the most utilized treatment for End Stage Kidney Disease (ESKD) globally, mainly as conventional HD administered in 4 h sessions thrice weekly. Despite advances in HD delivery, patients with ESKD carry a heavy cardiovascular morbidity and mortality burden. This is associated with cardiac remodeling, left ventricular hypertrophy (LVH), myocardial stunning, hypertension, decreased heart rate variability, sleep apnea, coronary calcification and endothelial dysfunction. Therefore, intensive HD regimens closer to renal physiology were developed. They include longer, more frequent dial...
Source: Current Vascular Pharmacology - April 1, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis A, Roumeliotis S, Chan C, Pierratos A Tags: Curr Vasc Pharmacol Source Type: research

Lifestyle, maternal nutrition and healthy pregnancy.
te;zquez CM Abstract Healthy lifestyle habits spanning from preconception to postpartum are considered as a major safeguard for achieving successful pregnancies and for prevention of gestational diseases. Among preconception priorities established by the World Health Organization (WHO) are healthy diet and nutrition, weight management, physical activity, planned pregnancy and physical, mental and psychosocial health. Most studies covering the topic of healthy pregnancies focus on maternal diet because obesity increases the risks for adverse perinatal outcomes, including gestational diabetes mellitus, large for ges...
Source: Current Vascular Pharmacology - April 1, 2020 Category: Drugs & Pharmacology Authors: Mate A, Reyes-Goya C, Santana-Garrido Á, Vázquez CM Tags: Curr Vasc Pharmacol Source Type: research

The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes.
Abstract Hypertension is a powerful risk factor for cardiovascular morbidity and mortality. High blood pressure (BP) correlates closely with all-cause and cardiovascular mortality. Although the gold standard still remains office BP (auscultatory or automated), other methods (central or out-of-office) are gaining popularity as better predictors of CV events. In this review, we investigated the prognostic value of each method of BP measurement and explored their advantages and pitfalls. Unattended automated office BP is a novel technique of BP measurement with promising data. Ambulatory BP monitoring, and to a lesse...
Source: Current Vascular Pharmacology - March 30, 2020 Category: Drugs & Pharmacology Authors: Bakogiannis C, Stavropoulos K, Papadopoulos C, Papademetriou V Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Complications of Sleep Disorders: A Better Night's Sleep for a Healthier Heart / From Bench to Bedside.
Abstract Sleep is essential to and an integral part of life and when lacking or disrupted, a multitude of mental and physical pathologies ensue, including cardiovascular (CV) disease, which increase health care costs. Several prospective studies and meta-analyses show that insomnia, short (9h) sleep and other sleep disorders are associated with an increased risk of hypertension, metabolic syndrome, myocardial infarction, heart failure, arrhythmias, CV disease risk and/or mortality. The mechanisms by which insomnia and other sleep disorders lead to increased CV risk may encompass inflammatory, immunological, neuro-...
Source: Current Vascular Pharmacology - March 24, 2020 Category: Drugs & Pharmacology Authors: Manolis TA, Manolis AA, Apostolopoulos E, Melita H, Manolis AS Tags: Curr Vasc Pharmacol Source Type: research

Metabolic adaptations to pregnancy in healthy and gestational diabetic pregnancies: the pancreas - placenta axis.
METABOLIC ADAPTATIONS TO PREGNANCY IN HEALTHY AND GESTATIONAL DIABETIC PREGNANCIES: THE PANCREAS - PLACENTA AXIS. Curr Vasc Pharmacol. 2020 Mar 20;: Authors: Hill D, Szlapinski SK Abstract Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimulated insulin release. Placentally-derived hormones and growth factors are central to the altere...
Source: Current Vascular Pharmacology - March 20, 2020 Category: Drugs & Pharmacology Authors: Hill D, Szlapinski SK Tags: Curr Vasc Pharmacol Source Type: research

Vitamin K for the treatment of cardiovascular disease in End-Stage Renal Disease patients: is there hope?
Abstract In Chronic Kidney Disease, vascular calcification (VC) is highly prevalent even at early stages and is gradually enhanced, along with disease progression to End-Stage Renal Disease (ESRD). The calcification pattern in uremia includes all types of mineralization and contributes to the heavy cardiovascular (CV) burden that is common in these patients. Ectopic mineralization is the result of the imbalance between inhibitors and promoters of vascular calcification, with the latter overwhelming the former. The most powerful, natural inhibitor of calcification is Matrix Gla Protein (MGP), a small vitamin K depe...
Source: Current Vascular Pharmacology - March 20, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V Tags: Curr Vasc Pharmacol Source Type: research

The Neuro-Vascular Consequence of Diabetes: Foot Amputation and Evaluation of its Risk Factors and Health-Related Economic Impact.
This study aimed to determine financial burden and risk factors associated with T2DM-related foot amputation. METHODS: Retrospective hospital-based study from January 2017 to December 2018. Patients with T2DM with and without amputation were enrolled. The direct medical costs of amputation along with various risk factors were determined. Risk factors were evaluated by logistic regression analysis. RESULTS: A total 1460 patients with T2DMwere included; 484 (33%) patients had an amputation. Mean total cost of below knee, fingers and toe amputation were 886.63±23.91, 263.35 ±19.58 and 166.68 ± 8...
Source: Current Vascular Pharmacology - March 20, 2020 Category: Drugs & Pharmacology Authors: Naqvi IH, Talib A, Naqvi SH, Yasin L, Rizvi NZ Tags: Curr Vasc Pharmacol Source Type: research

Non-Alcoholic Fatty Liver Disease and Vascular Disease.
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It is globally-projected that NAFLD will become increasingly prevalent, especially among children and younger adults. As such, even within the next few years, NAFLD will contribute considerably to the overall CVD burden. In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this ar...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Manousou P, Forlano R, Mullish BH, Nathwani R, Dhar A, Thursz M Tags: Curr Vasc Pharmacol Source Type: research

Inflammatory markers in cardiovascular disease; lessons learned and future perspectives.
CONCLUSION: There is significant evidence regarding the role of consolidated and novel inflammatory markers in the field of diagnosis and prognosis of CVD. However, multimarker model assessment, validation of cut-off values and cost-effectiveness analyses are required, in order for those markers to be integrated into daily clinical practice. PMID: 32188386 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Grassos H, Doumas M, Faselis C Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in patients with chronic obstructive pulmonary disease, obstructive sleep apnoea syndrome and overlap syndrome.
Abstract Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea syndrome (OSAS) are among the most prevalent chronic respiratory disorders. Accumulating data suggest that there is a significant burden of cardiovascular disease (CVD) in patients with COPD and OSAS, affecting negatively patients' quality of life and survival. Overlap syndrome (OS), i.e. the co-existence of both COPD and OSAS in the same patient, has an additional impact on cardiovascular system multiplying the risk of morbidity and mortality. The underlying mechanisms for the development of CVD in patients with either OSAS or COPD...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Voulgaris A, Archontogeorgis K, Steiropoulos P, Papanas N Tags: Curr Vasc Pharmacol Source Type: research

Prognostic significance of relative hyperglycemia after percutaneous coronary intervention in patients with and without recognized diabetes.
Abstract BACKGROUND: The research on the association between relative glycemic level post-percutaneous coronary intervention (PCI) and adverse prognosis in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients is relatively inadequate. OBJECTIVE: To identify whether the glycemic level post-PCI predicts adverse prognosis in NSTE-ACS patients. METHODS: Patients (n=2465) admitted with NSTE-ACS who underwent PCI were enrolled. The relative glycemic level post-procedure was calculated as blood glucose level post-PCI divided by HbA1c level, which was named post-procedural glycemic index (PGI). T...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Zhao Q, Zhang T, Cheng Y, Ma Y, Xu Y, Yang J, Zhou Y Tags: Curr Vasc Pharmacol Source Type: research

Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i.
Abstract Type 2 diabetes mellitus (T2DM) is a rapidly evolving global health issue associated with a markedly increased risk of cardiovascular (CV) morbidity and mortality. The hyperglycaemic milieu contributes to the development of CV complications via several pathological pathways, leading to increased arterial stiffness (AS), that can be considered as a predictor of CV events in patients with diabetes. The measurement of AS is increasingly used for the clinical assessment of patients. Several methodologies were used in large population studies to assess AS; the most commonly used is the pulse wave velocity (PWV...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Lamacchia O, Sorrentino MR Tags: Curr Vasc Pharmacol Source Type: research

Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence.
CONCLUSION: Our first-line therapy of hypertension in hemodialysis is the assessment and management of dry-weight and optimization of dialysis prescription. Based on the available clinical-trial evidence, we prescribe atenolol 3 times/week after dialysis as first-line pharmacological option of hypertension to our patients without specific indications for other agents. Long-acting dihydropyridines and ACEIs/ARBs are our second-line and third-line choices, respectively. We avoid using MRAs and await results from ongoing trials testing their safety and efficacy. In patients receiving maintenance hemodialysis, randomized trial...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Georgianos P, Agarwal R Tags: Curr Vasc Pharmacol Source Type: research

Could antioxidant supplementation delay progression of cardiovascular disease in end-stage renal disease patients?
Abstract In end-stage renal disease patients the leading causes of mortality are of cardiovascular origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. Notwithstanding, a contributing role of oxidative stress is postulated, which is increased even at early stages of chronic kidney disease, is gradually augmented in parallel to its progression to end-stage renal disease and is further accelerated by renal replacement therapies. Oxidative stress ensues when there is an imbalance between reactive pro-oxidants and physiologically occurring, ele...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Roumeliotis S, Roumeliotis A, Gorny X, Mertens P Tags: Curr Vasc Pharmacol Source Type: research

Vitamin D and vascular disease.
Abstract Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. Vitamin D deficiency has been identified as a potential risk factor for a number of diseases unrelated to the classical skeletal pathophysiology, such as cancer and CVD, but the effects of vitamin D supplementation are less clear. Purpose of this narrative review is to discuss the evidence suggesting an association between vitamin D status and CVD as well as the results of supplementation studies. Vitamin D deficiency has been associated with CVD risk factors such as hypertension, dyslipidemia and diabetes mellitus as well...
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Gouni-Berthold I, Berthold HK Tags: Curr Vasc Pharmacol Source Type: research

LncRNA MALAT1 Enhances ox-LDL-Induced Autophagy through the SIRT1/MAPK/NF- κB Pathway in Macrophages.
CONCLUSION: LncRNA MALAT1 Enhances Ox-LDL-induced Autophagy via the SIRT1/MAPK/NF-κB Pathway in Macrophages. PMID: 32183682 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 17, 2020 Category: Drugs & Pharmacology Authors: Yang J, Lin X, Wang LA, Sun T, Zhao Q, Ma Q, Zhou Y Tags: Curr Vasc Pharmacol Source Type: research

Fetal/Infant Origins of Adult Vascular Disease.
PMID: 32129165 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - March 4, 2020 Category: Drugs & Pharmacology Authors: Paraskevas KI, Briana DD, Malamitsi-Puchner A, Mikhailidis DP Tags: Curr Vasc Pharmacol Source Type: research

Assessment and management of volume overload among patients on chronic dialysis.
Abstract Volume overload is the most common complication in end-stage renal disease (ESRD) patients, being directly related to numerous complications including resistant hypertension, cardiac hypertrophy, congestive heart failure or arterial stiffness, among others. Therefore, volume overload is now considered an important risk factor for hard outcomes, like all-cause or cardiovascular mortality. Relying solely on clinical examination for assessing volume overload in ESRD patients lacks sensitivity and specificity. Numerous efforts have been made to identify new methods that could objectively assess volume status;...
Source: Current Vascular Pharmacology - February 24, 2020 Category: Drugs & Pharmacology Authors: Covic A, Siriopol D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular effects of biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Abstract The risk of cardiovascular (CV) disease is increased among patients with systemic autoimmune rheumatic diseases and remains an underserved area of medical need. Although traditional risk factors for CV disease, such as hypertension, smoking, dyslipidemia and obesity contribute to endothelial dysfunction in rheumatoid arthritis (RA), they are not enough on their own to explain the observed excess CV risk. Rather, systemic inflammation seems to play a pivotal role in both disease states. With a view to the inflammatory process in autoimmune diseases, scientific interest has focused on recently introduced bi...
Source: Current Vascular Pharmacology - February 13, 2020 Category: Drugs & Pharmacology Authors: Drakopoulou M, Soulaidopoulos S, Oikonomou G, Toutouzas K, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Management of Type 2 Diabetes Complications.
PMID: 32013814 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 6, 2020 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos K, Stavropoulos K, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.
CONCLUSION: Pharmaceutical approach of CVD in T2DM is multilevel and complex. Drug classes featuring pleiotropic effects may boost our armamentarium in the fight against CVD. PMID: 32013815 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 6, 2020 Category: Drugs & Pharmacology Authors: Patoulias D, Stavropoulos K, Imprialos K, Athyros V, Doumas M, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular disease in the Systemic Vasculitides.
Abstract The vasculitides are a heterogeneous group of disorders, characterized by inflammatory cell infiltration and necrosis of blood vessels that cause vascular obstruction or aneurysm formation, affecting various organs such as lungs, kidneys, skin and joints. Cardiac involvement is commonly encountered in primary systemic vasculitis and it is associated with increased morbidity and mortality. Depending on the dominant pathophysiological mechanism, heart complications may manifest in different ways, including myocardial ischemia due to impaired micro- or macrovascular circulation, progressive heart failure fol...
Source: Current Vascular Pharmacology - January 29, 2020 Category: Drugs & Pharmacology Authors: Soulaidopoulos S, Madenidou AV, Daoussis D, Melissaropoulos K, Mavrogeni S, Kitas G, Dimitroulas T Tags: Curr Vasc Pharmacol Source Type: research

Primary Sj ögren's Syndrome and Cardiovascular Disease.
Primary Sjögren's Syndrome and Cardiovascular Disease. Curr Vasc Pharmacol. 2020 Jan 29;: Authors: Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D Abstract Sjögren's syndrome is a rheumatic autoimmune disease that primarily affects middle-aged women and runs a slowly progressing course with sicca symptoms being the prevalent manifestation. Premature atherosclerosis and increased cardiovascular (CV) morbidity and mortality is frequently encountered in rheumatic diseases characterized by significant systemic inflammation, such as the inflammatory arthritides, syst...
Source: Current Vascular Pharmacology - January 29, 2020 Category: Drugs & Pharmacology Authors: Melissaropoulos K, Bogdanos D, Dimitroulas T, Sakkas LI, Kitas GD, Daoussis D Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular consequences of autoimmune rheumatic diseases.
CARDIOVASCULAR CONSEQUENCES OF AUTOIMMUNE RHEUMATIC DISEASES. Curr Vasc Pharmacol. 2020 Jan 27;: Authors: Atzeni F, Nucera V, Gerratana E, Fiorenza A, Gianturco L, Corda M, Sarzi-Puttini P Abstract The increased risk of cardiovascular disease (CVD) among patients with autoimmune rheumatic dis-eases such as rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus has been exten-sively documented. Sub-clinical atherosclerosis can be assessed using various non-invasive imaging techniques. However, the mechanisms underlying the greater risk of atherosclerotic CVD in patients with autoimmun...
Source: Current Vascular Pharmacology - January 27, 2020 Category: Drugs & Pharmacology Authors: Atzeni F, Nucera V, Gerratana E, Fiorenza A, Gianturco L, Corda M, Sarzi-Puttini P Tags: Curr Vasc Pharmacol Source Type: research

Novel Biomarkers/Predictors of Cardiovascular Disease and Cardiovascular Events.
on; P PMID: 31965944 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - January 21, 2020 Category: Drugs & Pharmacology Authors: Paraskevas KI, Ježovnik MK, Poredoš P Tags: Curr Vasc Pharmacol Source Type: research

Familial Hypercholesterolaemia Registry in the MENA Region.
PMID: 31880238 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 29, 2019 Category: Drugs & Pharmacology Authors: Kolovou G, Watts GF Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention.
CONCLUSION: SLE patients warrant regular assessment of their cardiovascular risk with prompt initiation of general and disease-specific risk-lowering strategies. Other: Further studies will be required regarding the use of non-invasive tools and biomarkers for cardiovascular assessment and of risk-lowering strategies tailored to SLE patients. PMID: 31880245 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 26, 2019 Category: Drugs & Pharmacology Authors: Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G Tags: Curr Vasc Pharmacol Source Type: research

Uric acid in metabolic and cerebrovascular disorders: a review.
CONCLUSION: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases. PMID: 31845632 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - December 17, 2019 Category: Drugs & Pharmacology Authors: Cortese F, Scicchitano P, Meliota G, Giordano P, Ciccone MM Tags: Curr Vasc Pharmacol Source Type: research

Screening for and Optimal Management of Small Abdominal Aortic Aneurysms: The Quest Continues.
PMID: 31769359 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - November 26, 2019 Category: Drugs & Pharmacology Authors: Paraskevas KI, Eckstein HH, Nicolaides AN, Geroulakos G Tags: Curr Vasc Pharmacol Source Type: research

Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients.
Abstract BACKGROUND: Osteoprotegerin and osteopontin have recently emerged as key factors in both vascular remodelling and atherosclerosis progression. Interleukin-6 (IL-6) is an inflammatory cytokine with a key role in atherosclerosis. The relationship of osteoprotegerin, osteopontin, and IL-6 serum levels with endothelial function and arterial stiffness was evaluated in patients with coronary artery disease (CAD). METHODS: We enrolled 219 patients with stable CAD and 112 control subjects. Osteoprotegerin, osteopontin and IL-6 serum levels were measured using an ELISA assay. Endothelial function was evaluate...
Source: Current Vascular Pharmacology - October 21, 2019 Category: Drugs & Pharmacology Authors: Maniatis K, Siasos G, Oikonomou E, Vavuranakis M, Zaromytidou M, Mourouzis K, Paraskevopoulos T, Charalambous G, Papavassiliou AG, Tousoulis D Tags: Curr Vasc Pharmacol Source Type: research

Pre- and Post-conditioning in Cardiovascular Surgery.
Abstract PMID: 31599710 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - October 12, 2019 Category: Drugs & Pharmacology Authors: Guerrero Orriach JL, Ramirez-Fernandez A Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular risk of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Abstract Patients with rheumatoid diseases have an increased risk of CVD and CVD-related death compared with the general population. Both the traditional cardiovascular risk factors and systemic inflammation are contributors to this phenomenon. This review examines the available evidence about the effects of synthetic, non-biologic disease-modifying antirheumatic drugs (DMARDs) in CVD risk. This is an important issue for clinicians when deciding on individual treatment plans in patients with rheumatic diseases. Evidence suggests that synthetic, non-biologic DMARDs such as methotrexate, sulfosalazine, hydroxychloro...
Source: Current Vascular Pharmacology - September 30, 2019 Category: Drugs & Pharmacology Authors: Mourouzis IS, Manolis AS, Pantos C Tags: Curr Vasc Pharmacol Source Type: research

Cardiovascular Disease in Antiphospholipid Syndrome.
Abstract Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by venous, arterial or microvascular thrombosis or obstetrical events in the presence of persistently positive antiphospholipid antibodies and constitutes a major cause of cardiovascular events in young people. Τhis review aims to highlight the pathophysiology of cardiovascular complications in patients with APS and possible treatment options. Patients with APS have endothelial dysfunction, accelerated proliferation and hyperplasia, atherogenesis, platelet activation and aggregation, inflammatory products secretion and coag...
Source: Current Vascular Pharmacology - August 29, 2019 Category: Drugs & Pharmacology Authors: Polytarchou K, Varvarousis D, Manolis AS Tags: Curr Vasc Pharmacol Source Type: research

Effects of Pregnancy-Induced Insulin Resistance on the Fetus and the Future Development of Metabolic Diseases in Adulthood.
PMID: 31441727 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 23, 2019 Category: Drugs & Pharmacology Authors: Briana DD, Malamitsi-Puchner A Tags: Curr Vasc Pharmacol Source Type: research

Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Talking Face to Face is Better than a Phone Call.
PMID: 31433760 [PubMed - as supplied by publisher] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 20, 2019 Category: Drugs & Pharmacology Authors: Metzinger-Le Meuth V, Metzinger L Tags: Curr Vasc Pharmacol Source Type: research

What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - August 17, 2019 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos K, Stavropoulos K, Athyros VG Tags: Curr Vasc Pharmacol Source Type: research

Insulin Therapy, Insulin Resistance and Vascular Dysfunction.
via L Abstract PMID: 31418345 [PubMed - in process] (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - August 17, 2019 Category: Drugs & Pharmacology Authors: Vázquez MC, Sobrevia L Tags: Curr Vasc Pharmacol Source Type: research